Loading…
Employees: 86
Size Orchestra BioMed (OBIO) is a United States Health Care company (Medical Specialties) with a market value of $341M, the 3005th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.68 on 6 Nov 2026.
Performance Over six months the shares gained 40.6%, against -9.6% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 986.1% over the last twelve months (peer median +5.3%); the operating margin is -181.4% (peer median 4.9%).
Valuation It trades at 9.8× enterprise value to sales against a peer median of 3.9× (3rd most expensive of 21).
Backlog Backlog (remaining performance obligations) was $11.0M at 31 Dec 2025, up 150% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 4.2% of the free float (15 Oct 2026).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $32.0M | $33.5M | $2.64M | $2.76M | $3.53M |
| Revenue growth | — | +1,169% | -4% | -22% | — |
| Gross profit | $31.5M | $33.1M | $2.28M | $2.43M | $3.21M |
| EBITDA | -$57.6M | -$51.5M | -$64.0M | -$51.2M | -$32.4M |
| Net income | -$59.0M | -$52.7M | -$61.0M | -$49.1M | -$33.6M |
| Free cash flow | -$59.1M | -$49.5M | -$50.8M | -$46.2M | -$29.9M |
| Capital expenditure | $781,000 | $489,000 | $289,000 | $78,000 | $591,000 |
| Total debt | $70.8M | $32.4M | $16.5M | $1.69M | $11.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OBIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -5.6% | 8th highest of 21 |
| 6-month return | +40.6% | -9.6% | 5th highest of 20 |
| Distance from 52-week high | -12.6% | -30.0% | 2nd highest of 21 |
| Revenue growth (TTM) | +986.1% | +5.3% | highest of 21 |
| Operating margin | -181.4% | 4.9% | 2nd lowest of 21 |
| EV / Sales | 9.8× | 3.9× | 3rd most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 1.6× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 2.9× | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | 23.6× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | 4.7× | 22.5% | -10.9% |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 4.8× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | 5.3× | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 2.4× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 3.1× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | 0.6× | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | 4.2× | 26.0% | -11.9% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |
Orchestra BioMed reported $11.0M of remaining performance obligations at 31 Dec 2025, up 150% from a year earlier. That is 0.3 years of trailing revenue already under contract.